Division of Surgical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
J Gastrointest Oncol. 2013 Sep;4(3):328-36. doi: 10.3978/j.issn.2078-6891.2013.032.
Colorectal cancer (CRC) is a leading worldwide health concern that is responsible for thousands of deaths each year. The primary source of mortality for patients with CRC is the development and subsequent progression of metastatic disease. The most common site for distant metastatic disease is the liver. Although patients with metastatic disease to the liver have several effective treatment options, the only one for cure remains surgical resection of the liver metastases. Historically, most patients with liver metastases have had unresectable disease, and only a small percentage of patients have undergone complete curative resection. However, improved systemic therapies have led to an evolution in strategies to treat metastatic CRC to the liver. Under most conditions the management of these patients remains complex; and as chemotherapy options and new targeted therapies continue to improve outcomes, it is clear that a multidisciplinary approach must be the foundation on which advanced surgical and medical techniques are employed. Here, in this review, we highlight the role of targeted therapies in the surgical management of patients with metastatic CRC to the liver.
结直肠癌（CRC）是一个全球性的健康问题，每年导致数千人死亡。CRC 患者死亡的主要原因是转移性疾病的发展和随后的进展。远处转移性疾病最常见的部位是肝脏。尽管患有肝转移的患者有几种有效的治疗选择，但唯一的治愈方法仍然是手术切除肝转移。从历史上看，大多数肝转移患者患有不可切除的疾病，只有一小部分患者接受了完全治愈性切除。然而，改善的系统治疗导致了治疗肝转移结直肠癌策略的演变。在大多数情况下，这些患者的管理仍然很复杂；随着化疗选择和新的靶向治疗继续改善结果，很明显，多学科方法必须是先进的手术和医学技术的基础。在这里，我们在这篇综述中强调了靶向治疗在肝转移结直肠癌患者的外科治疗中的作用。
